find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Pediatric Oncology
Phase II
Active
nct/study# NCT03919071 / COG-ACNS1723
A Phase 2 Study Of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation In Actively-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Learn More
Pediatric Oncology
Phase II
Active
nct/study# NCT03581292 / COG-ACNS1721
A Phase 2 Study Of Veliparib (ABT-888) And Local Irradiation, Followed By Maintenance Veliparib And Temozolomide, In Patients With Actively Diagnosed High-Grade Glioma (HGG) Without H3 K27M Or BRAFV600 Mutations
Learn More
Pediatric Oncology
Phase III
Active
nct/study# NCT04166409 / COG-ACNS1833
A Phase 3 Randomized Non-Inferiority Study Of Carboplatin And Vincristine Versus Selumetinib (NSC# 748727) In Actively Diagnosed Or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations Or Systemic Neurofibromatosis Type 1 (NF1)
Learn More
Phase 1 Clinical Trials
Phase I/II
Accepting Patients
nct/study# NCT04104776 / 0209-01
A Phase 1/2 Study Of CPI-0209 Monotherapy And In Combination With Other Therapy In Patients With Advanced Tumors
Learn More
Phase 1 Clinical Trials
Phase I/II
Accepting Patients
nct/study# NCT03997968 / CYT-0851-01-REFMAL-639
A Multi-Center, Open Label Phase 1/2 Study Of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
Learn More
Phase 1 Clinical Trials
Phase I
Accepting Patients
nct/study# NCT04612751 / DS1062-A-U104
A Phase 1b, Multicenter, 2-Part, Open-Label Study Of DS-1062a In Combination With Durvalumab In Subjects With Advanced Or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations And Previously Treated With Platinum-Based Chemotherapy With Or Without Prior Immunotherapy
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.